IDH2 and AL amyloidosis: Currently, several clinical trials, e.g., “A Study to Evaluate Myeloma-Developing Regimens Using Genomics (MyDRUG, NCT02884102)” for patients with ≥30% mutation of CDKN2C, FGFR3, KRAS, NRAS, BRAF V600E, IDH2, or translocation t(11;14), and “Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial, NCT02465060)” address this question.